Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Lung
Published in: Lung 2/2015

01-04-2015

The Effect of Different Comorbidities on Survival of Non-small Cells Lung Cancer Patients

Authors: Maria Iachina, Erik Jakobsen, Henrik Møller, Margreet Lüchtenborg, Anders Mellemgaard, Mark Krasnik, Anders Green

Published in: Lung | Issue 2/2015

Login to get access

Abstract

Purpose

Primary lung cancer is one of the most common types of cancers. Comorbidity has been shown to be a negative prognostic factor in the overall lung cancer population. The significance of the individual comorbidities is less well known. The purpose of this paper is to investigate the effect of each comorbid disease groups on survival.

Methods

The analysis is based on all patients with NSCLC who were registered in 2009–2011, in total 10,378 patients. To estimate the effect of each comorbidity group on the survival, we fitted a Cox regression model for each comorbidity group adjusting for age, sex, resection, and stage.

Results

Patients with cardiovascular comorbidity have a 30 % higher death rate [HR 1.30 with 95 % CI (1.13; 1.49)] than patients without comorbidity. Patients with diabetes and patients with cerebrovascular disorders and COPD have a 20 % excess mortality than patients without comorbidity: [HR 1.19 with CI (1.02; 1.39) for diabetes, HR 1.18 with CI (1.05; 1.33) for cerebrovascular disorders, and HR 1.20 with CI (1.10; 1.39 for COPD)].

Conclusion

Our study shows the importance of cardiovascular disease in lung cancer. Diabetes, cerebrovascular disorders, and COPD also have a significant impact on survival of NSCLC patients.
Literature
1.
Extermann M (2007) Interaction between comorbidity and cancer. Cancer Control 14(1):13–22PubMed
2.
Firat S, Byhardt RW, Gore E (2010) The effects of comorbidity and age on RTOG study enrollment in stage III non-small cell lung cancer patients who are eligible for RTOG studies. Int J Radiat Oncol Biol Phys 78(5):1394–1399CrossRefPubMed
3.
de Cos JS, Miravet L, Abal J et al (2008) Lung cancer survival in Spain and prognostic factors: a prospective, multiregional study. Lung Cancer 59:246–254CrossRefPubMed
4.
Tammemagi CM, Neslund-Dudas C, Simoff M, Kvale P (2003) Impact of comorbidity on lung cancer survival. Int J Cancer 103:792–802CrossRefPubMed
5.
Lüchtenborg M, Jakobsen E, Krasnik M et al (2012) The effect of comorbidity on stage-specific survival in resected non-small cell lung cancer patients. Eur J Cancer 48(18):3386–3395CrossRefPubMed
6.
Janssen-Heijnen ML, Schipper RM, Razenberg PP et al (1998) Prevalence of co-morbidity in lung cancer patients and its relationship with treatment: a population-based study. Lung Cancer 21:105–113CrossRefPubMed
7.
Nalbantov G, Kietselaer, Vandecasteele K et al (2013) Cardiac comorbidity is an independent risk factor for radiation-induced lung toxicity in lung cancer patients. Radiother Oncol 109:100–106CrossRefPubMed
8.
Mishra PK, Pandey R, Shackcloth MJ et al (2009) Cardiac comorbidity is not a risk factor for mortality and morbidity following surgery for primary non-small cell lung cancer. Eur J Cardiothorac Surg 35:439–443CrossRefPubMed
9.
Hatlen P, Grønberg BH, Langhammer A et al (2011) Prolonged survival in patients with lung cancer with diabetes mellitus. J Thorac Oncol 6(11):1810–1817CrossRefPubMed
10.
Inala A, Kaplana A, Kucukoner M et al (2014) Is diabetes mellitus a negative prognostic factor for the treatment of advanced non-small-cell lung cancer? Rev Port Pneumol 20(2):62–68
11.
Lopez-Encuentra A, Astudillo J, Cerezal J et al (2005) Prognostic value of chronic obstructive pulmonary disease in 2994 cases of lung cancer. Eur J Cardiothorac Surg 27:8–13CrossRefPubMed
12.
Deleuran T, Thomsen RW, Nørgaard M et al (2013) Comorbidity and survival of Danish lung cancer patients from 2000–2011: a population-based cohort study. Clin Epidemiol 5(Suppl 1):31–38CrossRefPubMedCentralPubMed
13.
Grose D, Devereux G, Milroy R (2011) Comorbidity in lung cancer: important but neglected. A review of the current literature. Clin Lung Cancer 12(4):207–211CrossRefPubMed
14.
Jakobsen E, Green A, Iachina M et al (2013) Nationwide quality improvement in lung cancer care: the Danish Lung Cancer Registry. J Thorac Oncol. 8:1238–1247CrossRefPubMed
15.
Andersen TF, Madsen M, Jørgensen J et al (1999) The Danish National Hospital Register. A valuable source of data for modern health sciences. Dan Med Bull 46:263–268PubMed
16.
Charlson ME, Pompei P, Ales KL et al (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373–383CrossRefPubMed
17.
Edwards BK, Noone A, Mariotto AB et al (2014) Annual Report to the Nation on the status of cancer, 1975–2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast or prostate cancer. Cancer 120(9):1290–1314
18.
Read WL, Tierney RM, Page NC et al (2004) Differential prognostic impact of comorbidity. J Clin Oncol 22:3099–3103CrossRefPubMed
19.
Birim Ö, Kappetein AP, Borgers AJJC (2005) Charlson comorbidity index as a predictor of long-term outcome after surgery for nonsmall cell lung cancer. Eur J Cadiothorac Surg 28:759–762CrossRef
20.
Asmis TR, Ding K, Seymour L et al (2008) Age and comorbidity as independent prognostic factors in the treatment of non-small-cell lung cancer: a review of National Cancer Institute of Canada Clinical Trials Group Trials. J Clin Oncol 26:54–59CrossRefPubMed
21.
Iachina M, Green A, Jakobsen E (2014) The direct and indirect impact of comorbidity on the survival of patients with non-small cell lung cancer: a combination of survival, staging and resection models with missing measurements in covariates. BMJ Open 4:e003846CrossRefPubMedCentralPubMed
22.
Sekine Y, Behnia M, Fujisawa T (2002) Impact of COPD on pulmonary complications and on long-term survival of patients undergoing surgery for NSCLC. Lung Cancer 37:95–101CrossRefPubMed
23.
Rijke JM, Schouten LJ, Velde GPM et al (2004) Influence of age, comorbidity and performance status on the choice of treatment for patients with non-small cell lung cancer; results of a population-based study. Lung Cancer 46:233–245CrossRefPubMed
Metadata
Title
The Effect of Different Comorbidities on Survival of Non-small Cells Lung Cancer Patients
Authors
Maria Iachina
Erik Jakobsen
Henrik Møller
Margreet Lüchtenborg
Anders Mellemgaard
Mark Krasnik
Anders Green
Publication date
01-04-2015
Publisher
Springer US
Published in
Lung / Issue 2/2015
Print ISSN: 0341-2040
Electronic ISSN: 1432-1750
DOI
https://doi.org/10.1007/s00408-014-9675-5

Other articles of this Issue 2/2015

Lung 2/2015 Go to the issue

OriginalPaper

YKL-40 Protein Correlates with the Phenotype of Asthma

Report

Profibrosing Effect of Angiotensin Converting Enzyme Inhibitors in Human Lung Fibroblasts

OriginalPaper

Continuous Positive Airways Pressure and Uvulopalatopharyngoplasty Improves Pulmonary Hypertension in Patients with Obstructive Sleep Apnoea

OriginalPaper

Impact of Environmental Air Pollutants on Disease Control in Asmathic Patients

OriginalPaper

Effects of Polluted Air on Cardiovascular and Hematological Parameters After Progressive Maximal Aerobic Exercise

Erratum

Erratum to: Palliative Interventional Pulmonology Procedures in the Incarcerated Population with Cancer: A Case Series
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits